Krystal Biotech, Inc. (KRYS) Cash Flow Statement

The consistent ability to generate operating cash flow in excess of net income suggests that the company's earnings are not overly reliant on non-cash accruals. Investors should monitor whether this conversion efficiency persists as the company shifts from initial patient bolus capture to a more predictable, maintenance-based revenue model.

The rapid trajectory toward high FCF margins suggests that the company has effectively leveraged its fixed-cost manufacturing infrastructure. This trend implies that future R&D investments for pipeline expansion may be funded internally without the need for dilutive financing, provided the current commercial momentum remains stable.

The relatively low capital intensity indicates that the company's primary value driver is its proprietary platform rather than heavy physical asset requirements. This structure appears to provide a significant buffer for profitability, though investors should watch for potential spikes in CapEx if the company scales manufacturing for new indications.

The volatility in working capital changes across the observed periods warrants further investigation, as it may reflect the timing of inventory build-ups or shifts in payor reimbursement cycles. A consistent positive trend in working capital management would further validate the company's operational maturity in the commercial market.

The initiation of share repurchases suggests management's confidence in the long-term durability of its cash flows. However, investors should monitor whether this capital deployment strategy remains balanced with the necessary R&D investment required to advance the company's pipeline beyond its current dermatology-focused indications.